am 251 has been researched along with Disease Models, Animal in 137 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 7.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| "The cannabinoid 1 (CB1 ) receptor inverse agonists/antagonists, rimonabant (SR141716, SR) and AM251, produce nausea and potentiate toxin-induced nausea by inverse agonism (rather than antagonism) of the CB1 receptor." | 7.79 | Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. ( Duncan, M; Parker, LA; Rock, EM; Sticht, MA; Stott, C, 2013) |
| "Like emotional symptoms such as anxiety, modulations in working memory are among the frequently-reported but controversial psychiatric symptoms associated with nicotine (NC) administration." | 7.79 | Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. ( Hayase, T, 2013) |
| ") suppressed the maintenance of mechanical and cold allodynia in the cisplatin and paclitaxel models." | 7.78 | The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. ( Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA, 2012) |
| "Corticosterone plasma levels, locomotor activity, adrenal gland weight and bone loss were increased in periodontitis and stress groups, and there was also less weight gain." | 7.78 | Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat. ( De Laurentiis, A; Elverdin, JC; Rettori, E; Rettori, V; Zorrilla Zubilete, M, 2012) |
| "This study aimed to investigate the effects of anandamide or arachidonylethanolamide (AEA), an endogenous cannabinoid receptor agonist, on intraocular inflammation in an endotoxin-induced uveitis (EIU) model in rabbits." | 7.77 | A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits. ( Altinsoy, A; Bagriacik, EU; Dileköz, E; Ercan, ZS; Ilhan, SÖ; Kul, O; Or, M; Sarioglu, Y; Seven, I; Tunccan, OG, 2011) |
| "Data indicate the existence of a link between serotonergic and endocannabinoid systems in the mechanisms underlying mood disorders caused by nicotine abstinence and suggest that these interactions are potential targets for pharmacological aid in smoking cessation." | 7.77 | Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal. ( Calapai, G; Caputi, AP; Mannucci, C; Navarra, M; Pieratti, A; Russo, GA, 2011) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 5.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 3.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| "It is aimed to investigate the possible contribution of cannabinoid system that supresses the nociceptive process by the activation of CB1 and CB2 receptors in central and peripheral levels of pain pathways, to the analgesic activity of protocatechuic acid." | 3.91 | Cannabinoid system involves in the analgesic effect of protocatechuic acid. ( Arslan, R; Bektas, N; Dikmen, DY; Okcay, Y, 2019) |
| "Previous studies have shown that social withdrawal in the phencyclidine (PCP) rat model of schizophrenia results from deficient endocannabinoid-induced activation of CB1 receptors." | 3.83 | Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system. ( Giuffrida, A; Seillier, A, 2016) |
| "Chemical stimulation of the lateral hypothalamus (LH) with carbachol induces antinociception which is antagonized by blockade of orexin receptors in some pain modulatory sites in the tail-flick test." | 3.83 | Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats. ( Esmaeili, MH; Ezzatpanah, S; Haghparast, A; Reisi, Z, 2016) |
| "The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials." | 3.81 | A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015) |
| " Such insights prompted us to investigate the influence of dorsal hippocampal (CA1) NMDA receptor agents on amnesia induced by cannabinoid CB1 receptor agonist, arachidonylcyclopropylamide (ACPA) in male mice." | 3.81 | The dual effect of CA1 NMDA receptor modulation on ACPA-induced amnesia in step-down passive avoidance learning task. ( Amin-Yavari, S; Ebrahimi-Ghiri, M; Nasehi, M; Torabi-Nami, M; Zarrindast, MR, 2015) |
| "Like emotional symptoms such as anxiety, modulations in working memory are among the frequently-reported but controversial psychiatric symptoms associated with nicotine (NC) administration." | 3.79 | Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. ( Hayase, T, 2013) |
| "The cannabinoid 1 (CB1 ) receptor inverse agonists/antagonists, rimonabant (SR141716, SR) and AM251, produce nausea and potentiate toxin-induced nausea by inverse agonism (rather than antagonism) of the CB1 receptor." | 3.79 | Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. ( Duncan, M; Parker, LA; Rock, EM; Sticht, MA; Stott, C, 2013) |
| ") suppressed the maintenance of mechanical and cold allodynia in the cisplatin and paclitaxel models." | 3.78 | The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. ( Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA, 2012) |
| "Corticosterone plasma levels, locomotor activity, adrenal gland weight and bone loss were increased in periodontitis and stress groups, and there was also less weight gain." | 3.78 | Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat. ( De Laurentiis, A; Elverdin, JC; Rettori, E; Rettori, V; Zorrilla Zubilete, M, 2012) |
| "This study aimed to investigate the effects of anandamide or arachidonylethanolamide (AEA), an endogenous cannabinoid receptor agonist, on intraocular inflammation in an endotoxin-induced uveitis (EIU) model in rabbits." | 3.77 | A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits. ( Altinsoy, A; Bagriacik, EU; Dileköz, E; Ercan, ZS; Ilhan, SÖ; Kul, O; Or, M; Sarioglu, Y; Seven, I; Tunccan, OG, 2011) |
| "Data indicate the existence of a link between serotonergic and endocannabinoid systems in the mechanisms underlying mood disorders caused by nicotine abstinence and suggest that these interactions are potential targets for pharmacological aid in smoking cessation." | 3.77 | Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal. ( Calapai, G; Caputi, AP; Mannucci, C; Navarra, M; Pieratti, A; Russo, GA, 2011) |
| "The conditioned gaping model of nausea in rats was used to compare the CB(1) receptor antagonist/inverse agonist, AM251, and the CB(1) receptor neutral antagonists, AM6527 (centrally and peripherally active) and AM6545 (peripherally active), in potentiating conditioned gaping produced by lithium chloride (LiCl) solution." | 3.76 | Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. ( Bedard, H; Lang, ST; Limebeer, CL; Makriyannis, A; Ossenkopp, KP; Parker, LA; Vemuri, VK, 2010) |
| "Both opioid and cannabinoid CB(1) receptors may be involved in the dramatic increase in pentylenetetrazole-induced seizure threshold in cholestasis." | 3.74 | Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: interaction between opioid and cannabinoid systems. ( Dehpour, AR; Ghasemi, M; Shafaroodi, H, 2008) |
| " Benzodiazepines can produce rapid effects, but their long-term use may result in severe adverse reaction and drug dependence." | 1.62 | Transcranial direct current stimulation (tDCS) produce anti-anxiety response in acute stress exposure rats via activation of amygdala CB1R. ( Fang, G; Wang, Y, 2021) |
| "AM404 attenuated mechanical and cold hyperalgesia with minimal effects on motor coordination." | 1.62 | Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model. ( Hara, K; Haranishi, Y; Terada, T, 2021) |
| "Similar to clinical PTSD, approximately 25-30% of rats that undergo cued fear conditioning exhibit impaired extinction learning." | 1.56 | Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder. ( Diwan, M; Giacobbe, P; Gidyk, DC; Gouveia, FV; Hamani, C; Lipsman, N; Nobrega, JN; Vimalanathan, A, 2020) |
| "Toxoplasmosis was established in mice by intraperitoneal injection of T." | 1.56 | Cannabinoid receptors and the proconvulsant effect of toxoplasmosis in mice. ( Babaie, J; Ghanbari, MM; Joneidi, M; Kiani, B; Sayyah, M, 2020) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 1.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "Obesity is a global public health problem." | 1.48 | Orexin-A and endocannabinoid signaling regulate glucose-responsive arcuate nucleus neurons and feeding behavior in obese rats. ( Guo, F; Sun, X; Wang, M; Xu, L; Yang, D; Zhang, D, 2018) |
| "Here, using a natural model of central sleep apnea, we examine the effects of dronabinol, alone and in combination with selective antagonists in conscious rats chronically instrumented to stage sleep and measure cessation of breathing." | 1.46 | Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats. ( Calik, MW; Carley, DW, 2017) |
| "It was suggested that in PTSD, hippocampal-dependent memory is compromised while amygdala-dependent memory is strengthened." | 1.46 | Cannabinoids prevent the differential long-term effects of exposure to severe stress on hippocampal- and amygdala-dependent memory and plasticity. ( Abush, H; Akirav, I; Mizrachi Zer-Aviv, T; Segev, A; Shoshan, N, 2017) |
| "MCS reversed mechanical hyperalgesia, inhibited astrocyte and microglial activity, decreased proinflammatory cytokine staining, enhanced CB2 staining, and downregulated P2X4 receptors in the DHSC ipsilateral to sciatic injury." | 1.42 | The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? ( Fonoff, ET; Lopes, PS; Pagano, RL; Silva, GD, 2015) |
| "Regarding the seizure-modulating properties of both classes of receptors, the present study aimed to evaluate the roles of the PPAR-gamma, PPAR-alpha and CB1 receptors on the anticonvulsant effects of WIN 55,212-2 (WIN, a non selective cannabinoid agonist)." | 1.42 | Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2. ( Aghaei, HN; Dehpour, AR; Ebrahimi, A; Gholizadeh, R; Gooshe, M; Mousavizadeh, K; Payandemehr, B; Rahimian, R; Varastehmoradi, B, 2015) |
| " Lethality was increased by AM251 with the higher dosage of PO, but no lethality was noted with either dosage of CPO, with or without AM251." | 1.42 | The cannabinoid receptor antagonist AM251 increases paraoxon and chlorpyrifos oxon toxicity in rats. ( Liu, J; Pope, C, 2015) |
| "Mean intraocular pressure was increased up to 88." | 1.39 | Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat. ( Pinar-Sueiro, S; Sharma, SC; Vecino, E; Veiga-Crespo, P; Zorrilla Hurtado, JÁ, 2013) |
| "To induce hyperalgesia, rat paws were treated with intraplantar prostaglandin E2 (PGE2, 2μg)." | 1.39 | Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors. ( Duarte, ID; Pacheco, Dda F; Romero, TR, 2013) |
| "Weight loss was greater with AM251 than could be accounted for by food restriction (∼25%), an effect likely mediated by the EE response to CB1R inhibition." | 1.38 | Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss. ( Achanfuo-Yeboah, J; Cunningham, PK; Faidley, T; Fong, TM; Heymsfield, SB; Hickey, G; Hora, D; Johnson-Levonas, AO; Nicolich, S; Strack, AM; Thompson, D, 2012) |
| "05-10 μg/mouse) produced antidepressant-like effect dose-dependently, whereas influenced the MBB in a biphasic manner (produced a U-shaped dose-response curve)." | 1.37 | Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. ( Jain, NS; Manna, SS; Umathe, SN, 2011) |
| "The long-term use of levodopa as a pharmacotherapy for Parkinson's disease is limited by the development of levodopa-induced dyskinesias." | 1.36 | The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. ( Dowd, E; Finn, DP; Gorman, AM; Walsh, S, 2010) |
| "Models of neuropathic pain are associated with elevated spinal levels of endocannabinoids (ECs) and altered expression of cannabinoid receptors on primary sensory afferents and post-synaptic cells in the spinal cord." | 1.36 | Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. ( Barrett, DA; Chapman, V; de Lago, E; Fernández-Ruiz, J; Gray, RA; Jhaveri, MD; Kendall, DA; Richardson, D; Sagar, DR, 2010) |
| "Using model of clonic seizure induced by pentylenetetrazole (PTZ) in male NMRI mice, we investigated whether NO is involved in the effects of cannabinoids on the seizure threshold." | 1.35 | Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1) agonist ACEA in the pentylenetetrazole-induced seizure in mice. ( Bahremand, A; Dehpour, AR; Ghasemi, M; Nasrabady, SE; Shafaroodi, H, 2009) |
| ", the compound consistently increased anxiety parameters in all of the three different anxiety tests applied, while a lower dosage of 1mg/kg had no such effect." | 1.35 | Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. ( Hasenöhrl, RU; Ledent, C; Molleman, A; Thiemann, G; Watt, CA, 2009) |
| "The NAGly induced anti-allodynia was dose dependent and, unlike HU-210, was unaffected by the cannabinoid CB(1) and CB(2) receptor antagonists, AM251 and SR144528 (30 nmol)." | 1.35 | Actions of N-arachidonyl-glycine in a rat neuropathic pain model. ( Mitchell, VA; Vaughan, CW; Vuong, LA, 2008) |
| "05-5pmol) induced anxiolytic-like effects with bell-shaped dose-response curves, the higher doses being ineffective." | 1.34 | Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. ( Aguiar, DC; Guimarães, FS; Moreira, FA, 2007) |
| "In models of Parkinson's disease, indirect-pathway eCB-LTD is absent but is rescued by a D2 receptor agonist or inhibitors of endocannabinoid degradation." | 1.34 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. ( Kreitzer, AC; Malenka, RC, 2007) |
| "Advanced liver cirrhosis is associated with hyperdynamic circulation consisting of systemic hypotension, decreased peripheral resistance, and cardiac dysfunction, termed cirrhotic cardiomyopathy." | 1.34 | Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. ( Bátkai, S; Harvey-White, J; Kechrid, R; Kunos, G; Mukhopadhyay, P; Pacher, P, 2007) |
| "Both mechanical allodynia and thermal hyperalgesia are seen both ipsilateral and contralateral to the side of nerve injury, but is significantly more severe ipsilaterally." | 1.34 | The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. ( Hsu, KS; Huang, CC; Liang, YC, 2007) |
| "Paracetamol dose-dependently decreased mechanical allodynia and lowered nociceptive scores associated with hyperalgesia testing." | 1.34 | The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. ( Beaulieu, P; Dani, M; Guindon, J; Lambert, C, 2007) |
| "However, regarding the seizure modulating properties of both classes of receptors this study investigated whether ultra-low dose cannabinoid antagonist AM251 influences cannabinoid anticonvulsant effects." | 1.34 | Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. ( Bahremand, A; Dehpour, AR; Ghasemi, M; Gholizadeh, S; Shafaroodi, H; Sharifzadeh, M, 2007) |
| "WIN 55,212-2 attenuated both heat and mechanical hyperalgesia dose-dependently." | 1.32 | Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. ( Johanek, LM; Simone, DA, 2004) |
| "Regarding the seizure-modulating properties of both classes of receptors, the present study examined the possibility of a functional interaction between these receptors." | 1.32 | The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. ( Dehpour, AR; Hajrasouliha, AR; Homayoun, H; Moezi, L; Sadeghipour, H; Samini, M; Shafaroodi, H; Tavakoli, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (24.82) | 29.6817 |
| 2010's | 91 (66.42) | 24.3611 |
| 2020's | 12 (8.76) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Liu, B | 1 |
| Tian, Y | 1 |
| Li, Y | 1 |
| Wu, P | 1 |
| Zhang, Y | 1 |
| Zheng, J | 1 |
| Shi, H | 1 |
| Rodrigues, FF | 1 |
| Morais, MI | 1 |
| Melo, ISF | 1 |
| Augusto, PSA | 1 |
| Dutra, MMGB | 1 |
| Costa, SOAM | 1 |
| Costa, FC | 1 |
| Goulart, FA | 1 |
| Braga, AV | 1 |
| Coelho, MM | 1 |
| Machado, RR | 1 |
| Vimalanathan, A | 1 |
| Gidyk, DC | 1 |
| Diwan, M | 1 |
| Gouveia, FV | 1 |
| Lipsman, N | 1 |
| Giacobbe, P | 1 |
| Nobrega, JN | 1 |
| Hamani, C | 1 |
| Ghanbari, MM | 1 |
| Joneidi, M | 1 |
| Kiani, B | 1 |
| Babaie, J | 1 |
| Sayyah, M | 1 |
| Rezaie, M | 1 |
| Nasehi, M | 4 |
| Vaseghi, S | 1 |
| Alimohammadzadeh, K | 1 |
| Islami Vaghar, M | 1 |
| Mohammadi-Mahdiabadi-Hasani, MH | 1 |
| Zarrindast, MR | 4 |
| Wi, R | 1 |
| Chung, YC | 1 |
| Jin, BK | 1 |
| Zhang, R | 2 |
| Lao, K | 1 |
| Lu, B | 1 |
| Guo, H | 1 |
| Cheng, J | 1 |
| Chen, P | 1 |
| Gou, X | 1 |
| Fang, G | 1 |
| Wang, Y | 1 |
| Haranishi, Y | 1 |
| Hara, K | 1 |
| Terada, T | 1 |
| Batista, LA | 2 |
| de Araújo Moreira, F | 1 |
| Aguiar, DC | 6 |
| Dahlén, A | 1 |
| Zarei, M | 1 |
| Melgoza, A | 1 |
| Wagle, M | 1 |
| Guo, S | 1 |
| Shoshan, N | 1 |
| Segev, A | 2 |
| Abush, H | 2 |
| Mizrachi Zer-Aviv, T | 1 |
| Akirav, I | 3 |
| Segat, GC | 1 |
| Manjavachi, MN | 1 |
| Matias, DO | 1 |
| Passos, GF | 1 |
| Freitas, CS | 1 |
| Costa, R | 1 |
| Calixto, JB | 1 |
| Calik, MW | 1 |
| Carley, DW | 1 |
| Simone, JJ | 1 |
| Baumbach, JL | 1 |
| McCormick, CM | 1 |
| Jing, N | 1 |
| Fang, B | 1 |
| Wang, ZL | 1 |
| Ma, H | 1 |
| Merali, Z | 1 |
| Cayer, C | 1 |
| Kent, P | 1 |
| Liu, R | 1 |
| Cal, V | 1 |
| Harris, CS | 1 |
| Arnason, JT | 1 |
| Wang, P | 1 |
| Zheng, T | 1 |
| Zhang, M | 1 |
| Xu, B | 1 |
| Zhang, T | 1 |
| Zhao, W | 1 |
| Shi, X | 1 |
| Zhang, Q | 1 |
| Fang, Q | 1 |
| Yang, D | 1 |
| Xu, L | 1 |
| Guo, F | 1 |
| Sun, X | 1 |
| Zhang, D | 1 |
| Wang, M | 1 |
| Giorno, TBS | 1 |
| Moreira, IGDS | 1 |
| Rezende, CM | 1 |
| Fernandes, PD | 1 |
| Suemaru, K | 1 |
| Yoshikawa, M | 1 |
| Aso, H | 1 |
| Watanabe, M | 3 |
| De Gregorio, D | 1 |
| McLaughlin, RJ | 3 |
| Posa, L | 1 |
| Ochoa-Sanchez, R | 1 |
| Enns, J | 1 |
| Lopez-Canul, M | 1 |
| Aboud, M | 1 |
| Maione, S | 1 |
| Comai, S | 1 |
| Gobbi, G | 1 |
| Shirzadian, A | 1 |
| Ostadhadi, S | 1 |
| Hassanipour, M | 1 |
| Shafaroodi, H | 6 |
| Khoshnoodi, M | 1 |
| Haj-Mirzaian, A | 3 |
| Sharifzadeh, M | 2 |
| Amiri, S | 2 |
| Ghasemi, M | 4 |
| Dehpour, AR | 8 |
| Stark, T | 1 |
| Ruda-Kucerova, J | 1 |
| Iannotti, FA | 1 |
| D'Addario, C | 1 |
| Di Marco, R | 1 |
| Pekarik, V | 1 |
| Drazanova, E | 1 |
| Piscitelli, F | 1 |
| Bari, M | 1 |
| Babinska, Z | 1 |
| Giurdanella, G | 1 |
| Di Bartolomeo, M | 1 |
| Salomone, S | 1 |
| Sulcova, A | 1 |
| Maccarrone, M | 1 |
| Wotjak, CT | 1 |
| Starcuk, Z | 1 |
| Drago, F | 2 |
| Mechoulam, R | 1 |
| Di Marzo, V | 4 |
| Micale, V | 2 |
| Leffa, DT | 1 |
| Ferreira, SG | 1 |
| Machado, NJ | 1 |
| Souza, CM | 1 |
| Rosa, FD | 1 |
| de Carvalho, C | 1 |
| Kincheski, GC | 1 |
| Takahashi, RN | 3 |
| Porciúncula, LO | 1 |
| Souza, DO | 1 |
| Cunha, RA | 1 |
| Pandolfo, P | 3 |
| Hartmann, A | 1 |
| Fassini, A | 1 |
| Scopinho, A | 1 |
| Correa, FM | 1 |
| Guimarães, FS | 6 |
| Lisboa, SF | 2 |
| Resstel, LB | 3 |
| Dikmen, DY | 1 |
| Okcay, Y | 1 |
| Arslan, R | 1 |
| Bektas, N | 1 |
| Pinar-Sueiro, S | 1 |
| Zorrilla Hurtado, JÁ | 1 |
| Veiga-Crespo, P | 1 |
| Sharma, SC | 1 |
| Vecino, E | 1 |
| Freitas, RL | 1 |
| Salgado-Rohner, CJ | 1 |
| Hallak, JE | 1 |
| Crippa, JA | 1 |
| Coimbra, NC | 2 |
| Almeida-Santos, AF | 2 |
| Gobira, PH | 2 |
| Rosa, LC | 1 |
| Moreira, FA | 6 |
| Magesto, AC | 1 |
| Aguiar, JC | 1 |
| Rock, EM | 1 |
| Sticht, MA | 1 |
| Duncan, M | 1 |
| Stott, C | 1 |
| Parker, LA | 2 |
| Reich, CG | 1 |
| Mihalik, GR | 1 |
| Iskander, AN | 1 |
| Seckler, JC | 1 |
| Weiss, MS | 1 |
| Rubin, AS | 1 |
| Richter-Levin, G | 1 |
| Anderson, WB | 1 |
| Gould, MJ | 1 |
| Torres, RD | 1 |
| Mitchell, VA | 3 |
| Vaughan, CW | 3 |
| Saglam, G | 1 |
| Gunduz, O | 1 |
| Ulugol, A | 1 |
| Wang, HN | 1 |
| Wang, L | 1 |
| Zhang, RG | 1 |
| Chen, YC | 1 |
| Liu, L | 1 |
| Gao, F | 1 |
| Nie, H | 1 |
| Hou, WG | 1 |
| Peng, ZW | 1 |
| Tan, Q | 1 |
| Sałaga, M | 1 |
| Mokrowiecka, A | 1 |
| Zakrzewski, PK | 1 |
| Cygankiewicz, A | 1 |
| Leishman, E | 2 |
| Sobczak, M | 1 |
| Zatorski, H | 1 |
| Małecka-Panas, E | 1 |
| Kordek, R | 1 |
| Storr, M | 1 |
| Krajewska, WM | 1 |
| Bradshaw, HB | 1 |
| Fichna, J | 1 |
| Wamsteeker Cusulin, JI | 1 |
| Senst, L | 1 |
| Teskey, GC | 1 |
| Bains, JS | 1 |
| Barry, MD | 1 |
| Boddington, LJ | 1 |
| Igelström, KM | 1 |
| Gray, JP | 1 |
| Shemmell, J | 1 |
| Tseng, KY | 1 |
| Oorschot, DE | 1 |
| Reynolds, JN | 1 |
| Gallo, A | 1 |
| Bouchard, C | 1 |
| Fortier, E | 1 |
| Ducrot, C | 1 |
| Rompré, PP | 1 |
| Bedse, G | 1 |
| Colangeli, R | 1 |
| Lavecchia, AM | 1 |
| Romano, A | 1 |
| Altieri, F | 1 |
| Cifani, C | 1 |
| Cassano, T | 1 |
| Gaetani, S | 2 |
| Arslan, G | 1 |
| Ayyildiz, M | 2 |
| Agar, E | 2 |
| Viana, TG | 1 |
| Hott, SC | 1 |
| Liu, J | 1 |
| Pope, C | 1 |
| Payandemehr, B | 1 |
| Ebrahimi, A | 1 |
| Gholizadeh, R | 1 |
| Rahimian, R | 1 |
| Varastehmoradi, B | 1 |
| Gooshe, M | 1 |
| Aghaei, HN | 1 |
| Mousavizadeh, K | 1 |
| Silva, GD | 1 |
| Lopes, PS | 1 |
| Fonoff, ET | 1 |
| Pagano, RL | 1 |
| Bastos, JR | 1 |
| Zhao, Q | 1 |
| Liang, X | 1 |
| Han, H | 1 |
| Kruk-Slomka, M | 2 |
| Michalak, A | 1 |
| Biala, G | 2 |
| Amin-Yavari, S | 1 |
| Ebrahimi-Ghiri, M | 1 |
| Torabi-Nami, M | 1 |
| Malek, N | 1 |
| Mrugala, M | 1 |
| Makuch, W | 1 |
| Kolosowska, N | 1 |
| Przewlocka, B | 1 |
| Binkowski, M | 1 |
| Czaja, M | 1 |
| Morera, E | 1 |
| Starowicz, K | 1 |
| Qin, M | 1 |
| Zeidler, Z | 1 |
| Moulton, K | 1 |
| Krych, L | 1 |
| Xia, Z | 1 |
| Smith, CB | 1 |
| Rabasa, C | 1 |
| Pastor-Ciurana, J | 1 |
| Delgado-Morales, R | 1 |
| Gómez-Román, A | 1 |
| Carrasco, J | 1 |
| Gagliano, H | 1 |
| García-Gutiérrez, MS | 1 |
| Manzanares, J | 1 |
| Armario, A | 1 |
| Carletti, F | 2 |
| Gambino, G | 1 |
| Rizzo, V | 2 |
| Ferraro, G | 2 |
| Sardo, P | 2 |
| Lee, TT | 2 |
| Hill, MN | 4 |
| Hillard, CJ | 3 |
| Gorzalka, BB | 4 |
| Khodayar, E | 1 |
| Oryan, S | 1 |
| Speed, HE | 1 |
| Masiulis, I | 1 |
| Gibson, JR | 1 |
| Powell, CM | 1 |
| Seillier, A | 1 |
| Giuffrida, A | 1 |
| Bakali, E | 1 |
| Mbaki, Y | 1 |
| Lambert, DG | 1 |
| Elliott, RA | 1 |
| Mason, R | 1 |
| Tincello, DG | 1 |
| Dos Anjos-Garcia, T | 1 |
| Ullah, F | 1 |
| Falconi-Sobrinho, LL | 1 |
| Carey, LM | 1 |
| Slivicki, RA | 1 |
| Cornett, B | 1 |
| Mackie, K | 3 |
| Bradshaw, H | 1 |
| Hohmann, AG | 2 |
| Nedaei, SE | 1 |
| Rezayof, A | 1 |
| Pourmotabbed, A | 1 |
| Esmaeili, MH | 2 |
| Reisi, Z | 2 |
| Ezzatpanah, S | 2 |
| Haghparast, A | 3 |
| Veeraraghavan, P | 1 |
| Dekanic, A | 1 |
| Nistri, A | 1 |
| Zhang, RS | 1 |
| He, Z | 1 |
| Jin, WD | 1 |
| Wang, R | 1 |
| Budzynska, B | 1 |
| Slomka, T | 1 |
| Banaszkiewicz, I | 1 |
| Costa, MDC | 1 |
| Ashraf, NS | 1 |
| Fischer, S | 1 |
| Yang, Y | 1 |
| Schapka, E | 1 |
| Joshi, G | 1 |
| McQuade, TJ | 1 |
| Dharia, RM | 1 |
| Dulchavsky, M | 1 |
| Ouyang, M | 1 |
| Cook, D | 1 |
| Sun, D | 1 |
| Larsen, MJ | 1 |
| Gestwicki, JE | 1 |
| Todi, SV | 1 |
| Ivanova, MI | 1 |
| Paulson, HL | 1 |
| Amini-Khoei, H | 1 |
| Ghesmati, M | 1 |
| Zahir, M | 1 |
| Sagar, DR | 2 |
| Kendall, DA | 2 |
| Chapman, V | 2 |
| Thiemann, G | 1 |
| Watt, CA | 1 |
| Ledent, C | 1 |
| Molleman, A | 1 |
| Hasenöhrl, RU | 1 |
| Bahremand, A | 2 |
| Nasrabady, SE | 1 |
| Vendruscolo, LF | 1 |
| Sordi, R | 1 |
| Kozan, R | 1 |
| Umathe, SN | 2 |
| Manna, SS | 2 |
| Utturwar, KS | 1 |
| Jain, NS | 2 |
| Cristino, L | 1 |
| Tamburella, A | 1 |
| Petrosino, S | 2 |
| Leggio, GM | 1 |
| Lonobile, G | 1 |
| Cannizzaro, C | 1 |
| Nawata, Y | 1 |
| Hiranita, T | 1 |
| Yamamoto, T | 1 |
| Telleria-Diaz, A | 1 |
| Schmidt, M | 1 |
| Kreusch, S | 1 |
| Neubert, AK | 1 |
| Schache, F | 1 |
| Vazquez, E | 1 |
| Vanegas, H | 1 |
| Schaible, HG | 1 |
| Ebersberger, A | 1 |
| Sink, KS | 1 |
| Segovia, KN | 1 |
| Sink, J | 1 |
| Randall, PA | 1 |
| Collins, LE | 1 |
| Correa, M | 1 |
| Markus, EJ | 1 |
| Vemuri, VK | 3 |
| Makriyannis, A | 3 |
| Salamone, JD | 1 |
| van Rijn, CM | 1 |
| Santolini, I | 1 |
| Badura, A | 1 |
| Gabova, A | 1 |
| Fu, J | 1 |
| Cuomo, V | 1 |
| van Luijtelaar, G | 1 |
| Nicoletti, F | 1 |
| Ngomba, RT | 1 |
| Guidali, C | 2 |
| Viganò, D | 2 |
| Zamberletti, E | 1 |
| Realini, N | 2 |
| Binelli, G | 1 |
| Rubino, T | 2 |
| Parolaro, D | 2 |
| Curto-Reyes, V | 1 |
| Llames, S | 1 |
| Hidalgo, A | 1 |
| Menéndez, L | 1 |
| Baamonde, A | 1 |
| Jhaveri, MD | 1 |
| Richardson, D | 1 |
| Gray, RA | 1 |
| de Lago, E | 1 |
| Fernández-Ruiz, J | 1 |
| Barrett, DA | 1 |
| Yang, YY | 1 |
| Liu, H | 2 |
| Nam, SW | 1 |
| Kunos, G | 2 |
| Lee, SS | 2 |
| Limebeer, CL | 1 |
| Bedard, H | 1 |
| Lang, ST | 1 |
| Ossenkopp, KP | 1 |
| Walsh, S | 1 |
| Gorman, AM | 1 |
| Finn, DP | 1 |
| Dowd, E | 1 |
| Rojo, ML | 1 |
| Söderström, I | 1 |
| Fowler, CJ | 1 |
| Schuelert, N | 1 |
| Johnson, MP | 1 |
| Oskins, JL | 1 |
| Jassal, K | 1 |
| Chambers, MG | 1 |
| McDougall, JJ | 1 |
| Dillon, GM | 1 |
| Lubbers, LS | 1 |
| Ferguson, MT | 1 |
| Lao, JZ | 1 |
| Huang, RR | 1 |
| Xiao, JC | 1 |
| Fong, TM | 2 |
| Hale, JJ | 1 |
| Rupprecht, K | 1 |
| Miao, S | 1 |
| Rowe, BA | 1 |
| Kornecook, TJ | 1 |
| Dodart, JC | 1 |
| Mannucci, C | 1 |
| Navarra, M | 1 |
| Pieratti, A | 1 |
| Russo, GA | 1 |
| Caputi, AP | 1 |
| Calapai, G | 1 |
| Dono, LM | 1 |
| Currie, PJ | 1 |
| Pan, B | 1 |
| Fitzgerald, ML | 1 |
| Roberts, CJ | 1 |
| Karatsoreos, IN | 1 |
| Viau, V | 2 |
| Pickel, VM | 1 |
| McEwen, BS | 1 |
| Liu, QS | 1 |
| Altinsoy, A | 1 |
| Dileköz, E | 1 |
| Kul, O | 1 |
| Ilhan, SÖ | 1 |
| Tunccan, OG | 1 |
| Seven, I | 1 |
| Bagriacik, EU | 1 |
| Sarioglu, Y | 1 |
| Or, M | 1 |
| Ercan, ZS | 1 |
| Ebrahimzadeh, M | 1 |
| Ganon-Elazar, E | 1 |
| Ho, YC | 1 |
| Lee, HJ | 1 |
| Tung, LW | 1 |
| Liao, YY | 1 |
| Fu, SY | 1 |
| Teng, SF | 1 |
| Liao, HT | 1 |
| Chiou, LC | 1 |
| Strack, AM | 1 |
| Nicolich, S | 1 |
| Faidley, T | 1 |
| Achanfuo-Yeboah, J | 1 |
| Cunningham, PK | 1 |
| Hora, D | 1 |
| Thompson, D | 1 |
| Hickey, G | 1 |
| Johnson-Levonas, AO | 1 |
| Heymsfield, SB | 1 |
| Chiodi, V | 1 |
| Uchigashima, M | 1 |
| Beggiato, S | 1 |
| Ferrante, A | 1 |
| Armida, M | 1 |
| Martire, A | 1 |
| Potenza, RL | 1 |
| Ferraro, L | 1 |
| Tanganelli, S | 1 |
| Domenici, MR | 1 |
| Popoli, P | 1 |
| Adamczyk, P | 1 |
| Miszkiel, J | 1 |
| McCreary, AC | 1 |
| Filip, M | 1 |
| Papp, M | 1 |
| Przegaliński, E | 1 |
| Rettori, E | 1 |
| De Laurentiis, A | 1 |
| Zorrilla Zubilete, M | 1 |
| Rettori, V | 1 |
| Elverdin, JC | 1 |
| Suzuki, N | 1 |
| Suzuki, M | 1 |
| Hamajo, K | 1 |
| Murakami, K | 1 |
| Tsukamoto, T | 1 |
| Shimojo, M | 1 |
| Deng, L | 1 |
| Guindon, J | 3 |
| Thakur, GA | 1 |
| White, FA | 1 |
| Romero, TR | 1 |
| Pacheco, Dda F | 1 |
| Duarte, ID | 2 |
| Cao, MH | 1 |
| Li, YY | 1 |
| Xu, J | 1 |
| Feng, YJ | 1 |
| Lin, XH | 1 |
| Li, K | 1 |
| Han, T | 1 |
| Chen, CJ | 1 |
| Campos, AC | 1 |
| Ortega, Z | 1 |
| Palazuelos, J | 1 |
| Fogaça, MV | 1 |
| Díaz-Alonso, J | 1 |
| Ortega-Gutiérrez, S | 1 |
| Vázquez-Villa, H | 1 |
| Guzmán, M | 1 |
| Galve-Roperh, I | 1 |
| Hayase, T | 1 |
| Johanek, LM | 1 |
| Simone, DA | 1 |
| Samini, M | 1 |
| Moezi, L | 2 |
| Homayoun, H | 1 |
| Sadeghipour, H | 1 |
| Tavakoli, S | 1 |
| Hajrasouliha, AR | 1 |
| Gardiner, SM | 2 |
| March, JE | 1 |
| Kemp, PA | 1 |
| Bennett, T | 2 |
| Matsuda, K | 1 |
| Mikami, Y | 1 |
| Takeda, K | 1 |
| Fukuyama, S | 1 |
| Egawa, S | 1 |
| Sunamura, M | 1 |
| Maruyama, I | 1 |
| Matsuno, S | 1 |
| De Léan, A | 1 |
| Beaulieu, P | 2 |
| Ho, WS | 1 |
| Sinopoli, KJ | 1 |
| Howard, AL | 1 |
| Neu, A | 1 |
| Morgan, RJ | 1 |
| Echegoyen, JC | 1 |
| Soltesz, I | 1 |
| Gaskari, SA | 1 |
| Baik, SK | 1 |
| Deshpande, LS | 2 |
| Sombati, S | 2 |
| Blair, RE | 2 |
| Carter, DS | 1 |
| Martin, BR | 2 |
| DeLorenzo, RJ | 2 |
| Wheal, AJ | 1 |
| Randall, MD | 1 |
| Kreitzer, AC | 1 |
| Malenka, RC | 1 |
| Nagarkatti, N | 1 |
| Ballmaier, M | 1 |
| Bortolato, M | 1 |
| Rizzetti, C | 1 |
| Zoli, M | 1 |
| Gessa, G | 1 |
| Heinz, A | 1 |
| Spano, P | 1 |
| Pamplona, FA | 1 |
| Prediger, RD | 1 |
| Bátkai, S | 1 |
| Mukhopadhyay, P | 1 |
| Harvey-White, J | 1 |
| Kechrid, R | 1 |
| Pacher, P | 1 |
| Liang, YC | 1 |
| Huang, CC | 1 |
| Hsu, KS | 1 |
| Vuong, LA | 1 |
| Dani, M | 1 |
| Lambert, C | 1 |
| Valenti, M | 1 |
| Massi, P | 1 |
| Morrish, AC | 1 |
| Gholizadeh, S | 1 |
| Greenwood, R | 1 |
| Jayamanne, A | 1 |
| Hajós, M | 1 |
| Hoffmann, WE | 1 |
| Kocsis, B | 1 |
| da Fonseca Pacheco, D | 1 |
| Klein, A | 1 |
| de Castro Perez, A | 1 |
| da Fonseca Pacheco, CM | 1 |
| de Francischi, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet[NCT04088929] | Phase 2 | 32 participants (Actual) | Interventional | 2019-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT04679545] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | ||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT05766969] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-20 | Recruiting | ||
| Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms[NCT05142267] | 120 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
137 other studies available for am 251 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
ACEA Attenuates Oxidative Stress by Promoting Mitophagy via CB1R/Nrf1/PINK1 Pathway after Subarachnoid Hemorrhage in Rats.
Topics: Animals; Antioxidants; Apoptosis; Arachidonic Acids; Disease Models, Animal; Gene Knockdown Techniqu | 2022 |
Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan; | 2020 |
Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder.
Topics: Animals; Anxiety; Benzamides; Benzoxazines; Carbamates; Conditioning, Psychological; Disease Models, | 2020 |
Cannabinoid receptors and the proconvulsant effect of toxoplasmosis in mice.
Topics: Animals; Benzodioxoles; Cannabinoids; Disease Models, Animal; Indoles; Male; Mice; Piperidines; Pyra | 2020 |
The interaction effect of sleep deprivation and cannabinoid type 1 receptor in the CA1 hippocampal region on passive avoidance memory, depressive-like behavior and locomotor activity in rats.
Topics: Animals; Arachidonic Acids; Avoidance Learning; Behavior, Animal; CA1 Region, Hippocampal; Cannabino | 2021 |
Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Capsaicin; Disease Models, Animal; Dopaminerg | 2020 |
(m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Disease Models, Animal; Endocannabinoids; Hemoglo | 2021 |
Transcranial direct current stimulation (tDCS) produce anti-anxiety response in acute stress exposure rats via activation of amygdala CB1R.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Male; Piperidines; Pyrazoles; | 2021 |
Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.
Topics: Animals; Arachidonic Acids; Capsaicin; Constriction; Disease Models, Animal; Endocannabinoids; Hyper | 2021 |
Interactions between the nitrergic and the endocannabinoid system in rats exposed to the elevated T-maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Disease Models, Animal; Endocannabinoids; L | 2021 |
THC-induced behavioral stereotypy in zebrafish as a model of psychosis-like behavior.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dronabinol; N-Methylaspartate; Piperidines; Psych | 2021 |
Cannabinoids prevent the differential long-term effects of exposure to severe stress on hippocampal- and amygdala-dependent memory and plasticity.
Topics: Amidohydrolases; Amygdala; Animals; Avoidance Learning; Benzamides; Benzoxazines; Bromine; Cannabino | 2017 |
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phyto | 2017 |
Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dr | 2017 |
Effects of CB1 receptor antagonism and stress exposures in adolescence on socioemotional behaviours, neuroendocrine stress responses, and expression of relevant proteins in the hippocampus and prefrontal cortex in rats.
Topics: Age Factors; Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Corticosterone; Cyclic AMP | 2018 |
Remote Ischemia Preconditioning Attenuates Blood-Spinal Cord Barrier Breakdown in Rats Undergoing Spinal Cord Ischemia Reperfusion Injury: Associated with Activation and Upregulation of CB1 and CB2 Receptors.
Topics: Animals; Disease Models, Animal; Down-Regulation; Femoral Artery; Indoles; Ischemic Preconditioning; | 2017 |
Sacred Maya incense, copal (Protium copal - Burseraceae), has antianxiety effects in animal models.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Burseraceae; Carrier Proteins; Ceremonial B | 2018 |
Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Topics: Acetic Acid; Analgesics; Animals; Area Under Curve; Disease Models, Animal; Dose-Response Relationsh | 2018 |
Orexin-A and endocannabinoid signaling regulate glucose-responsive arcuate nucleus neurons and feeding behavior in obese rats.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Disease Models, Animal; Endocannabinoids; Feeding Behavior | 2018 |
New
Topics: Analgesics; Animals; Behavior, Animal; Capsaicin; Coffee; Disease Models, Animal; Female; Formaldehy | 2018 |
TRPV1 mediates the anticonvulsant effects of acetaminophen in mice.
Topics: Acetaminophen; Acetanilides; Acrylamides; Animals; Anticonvulsants; Bridged Bicyclo Compounds, Heter | 2018 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Acute foot-shock stress decreased seizure susceptibility against pentylenetetrazole-induced seizures in mice: Interaction between endogenous opioids and cannabinoids.
Topics: Analgesics, Opioid; Animals; Cannabinoid Receptor Antagonists; Convulsants; Disease Models, Animal; | 2018 |
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.
Topics: Amides; Animals; Arachidonic Acids; Cannabidiol; Disease Models, Animal; Endocannabinoids; Ethanolam | 2019 |
Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Benzoxazines; Caffeine; Cannabinoid Receptor | 2019 |
Role of the endocannabinoid system in the dorsal hippocampus in the cardiovascular changes and delayed anxiety-like effect induced by acute restraint stress in rats.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Arterial Pressure; Behavior, Animal; Benzamide | 2019 |
Cannabinoid system involves in the analgesic effect of protocatechuic acid.
Topics: Acetic Acid; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxyb | 2019 |
Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat.
Topics: Administration, Topical; Animals; Benzoxazines; Cell Count; Disease Models, Animal; Female; Intraocu | 2013 |
Involvement of prelimbic medial prefrontal cortex in panic-like elaborated defensive behaviour and innate fear-induced antinociception elicited by GABAA receptor blockade in the dorsomedial and ventromedial hypothalamic nuclei: role of the endocannabinoid
Topics: Analysis of Variance; Animals; Bicuculline; Defense Mechanisms; Disease Models, Animal; Dose-Respons | 2013 |
Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray.
Topics: Analysis of Variance; Animals; Anxiety; Arachidonic Acids; Biphenyl Compounds; Cannabinoid Receptor | 2013 |
Complex interaction between anandamide and the nitrergic system in the dorsolateral periaqueductal gray to modulate anxiety-like behavior in rats.
Topics: Animals; Anxiety; Apomorphine; Arachidonic Acids; Bicuculline; Cannabinoid Receptor Agonists; Diseas | 2013 |
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dron | 2013 |
Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity.
Topics: Animals; Benzoxazines; Chronic Disease; Disease Models, Animal; Excitatory Postsynaptic Potentials; | 2013 |
Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression.
Topics: Animals; Avoidance Learning; Benzoxazines; Body Weight; Cannabinoid Receptor Agonists; Cannabinoid R | 2014 |
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
Topics: Amidohydrolases; Analgesics; Analysis of Variance; Animals; Arthritis, Experimental; Benzamides; Ben | 2014 |
Blockade of cannabinoid CB1 and CB2 receptors does not prevent the antipruritic effect of systemic paracetamol.
Topics: Acetaminophen; Animals; Antipruritics; Camphanes; Disease Models, Animal; Dose-Response Relationship | 2014 |
Anti-depressive mechanism of repetitive transcranial magnetic stimulation in rat: the role of the endocannabinoid system.
Topics: Analysis of Variance; Animals; bcl-2-Associated X Protein; Brain-Derived Neurotrophic Factor; Bromod | 2014 |
Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH).
Topics: Amidohydrolases; Animals; Cannabinoids; Colitis, Ulcerative; Disease Models, Animal; Dose-Response R | 2014 |
Experience salience gates endocannabinoid signaling at hypothalamic synapses.
Topics: Analgesics; Animals; Animals, Newborn; Benzoxazines; Disease Models, Animal; Dose-Response Relations | 2014 |
Utility of intracerebral theta burst electrical stimulation to attenuate interhemispheric inhibition and to promote motor recovery after cortical injury in an animal model.
Topics: Animals; Biophysics; Brain Injuries; Disease Models, Animal; Electroencephalography; Functional Late | 2014 |
Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Benzoxazines; Brain; Brain Injuries; C | 2014 |
Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress.
Topics: Analysis of Variance; Animals; Basolateral Nuclear Complex; Benzamides; Carbamates; Corticotropin-Re | 2014 |
The interaction between ghrelin and cannabinoid systems in penicillin-induced epileptiform activity in rats.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Ant | 2014 |
Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Dise | 2015 |
The cannabinoid receptor antagonist AM251 increases paraoxon and chlorpyrifos oxon toxicity in rats.
Topics: Amidohydrolases; Analysis of Variance; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Ca | 2015 |
Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2.
Topics: Anilides; Animals; Anticonvulsants; Benzoxazines; Cannabinoid Receptor Antagonists; Disease Models, | 2015 |
The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Cytokines; Deep B | 2015 |
Role of endocannabinoid signalling in the dorsolateral periaqueductal grey in the modulation of distinct panic-like responses.
Topics: Animals; Arachidonic Acids; Benzamides; Carbamates; Disease Models, Animal; Dose-Response Relationsh | 2015 |
[Cannabinoid receptor 1 controls nerve growth in ectopic cyst in a rat endometriosis model].
Topics: Animals; Blotting, Western; Cysts; Disease Models, Animal; Endometriosis; Female; Peripheral Nerves; | 2014 |
Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system.
Topics: Animals; Antidepressive Agents; Cannabinoids; Depressive Disorder; Disease Models, Animal; Indoles; | 2015 |
The dual effect of CA1 NMDA receptor modulation on ACPA-induced amnesia in step-down passive avoidance learning task.
Topics: 2-Amino-5-phosphonovalerate; Amnesia; Analysis of Variance; Animals; Arachidonic Acids; Avoidance Le | 2015 |
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides | 2015 |
Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Avoidance Learning; Benzamides; Cannabinoid Re | 2015 |
Evidence against a critical role of CB1 receptors in adaptation of the hypothalamic-pituitary-adrenal axis and other consequences of daily repeated stress.
Topics: Adaptation, Psychological; Adrenocorticotropic Hormone; Animals; Body Weight; Cannabinoid Receptor A | 2015 |
Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
Topics: Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dose-Res | 2015 |
Disruption of peri-adolescent endocannabinoid signaling modulates adult neuroendocrine and behavioral responses to stress in male rats.
Topics: Adaptation, Psychological; Adrenocorticotropic Hormone; Animals; Brain; Cannabinoid Receptor Antagon | 2015 |
Effect of nucleus accumbens shell 5-HT4 receptors on the impairment of ACPA-induced emotional memory consolidation in male Wistar rats.
Topics: Aniline Compounds; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonists; Disease Models, Ani | 2016 |
Increased Cortical Inhibition in Autism-Linked Neuroligin-3R451C Mice Is Due in Part to Loss of Endocannabinoid Signaling.
Topics: Amino Acid Substitution; Animals; Autistic Disorder; Cell Adhesion Molecules, Neuronal; Disease Mode | 2015 |
Role of the endocannabinoid 2-arachidonoylglycerol in aversive responses mediated by the dorsolateral periaqueductal grey.
Topics: Animals; Arachidonic Acids; Biphenyl Compounds; Cannabinoid Receptor Antagonists; Disease Models, An | 2016 |
Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.
Topics: Analysis of Variance; Animals; Cannabinoid Receptor Modulators; Cyclohexanols; Discrimination, Psych | 2016 |
Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats.
Topics: Acetic Acid; Administration, Intravesical; Animals; Cannabinoid Receptor Agonists; Cyclohexanols; Di | 2016 |
CB
Topics: Animals; Arachidonic Acids; Bicuculline; Disease Models, Animal; Endocannabinoids; Escape Reaction; | 2017 |
A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Topics: Acrylamides; Amidohydrolases; Analgesia; Animals; Arachidonic Acid; Bridged Bicyclo Compounds, Heter | 2016 |
Activation of endocannabinoid system in the rat basolateral amygdala improved scopolamine-induced memory consolidation impairment.
Topics: Animals; Arachidonic Acids; Avoidance Learning; Basolateral Nuclear Complex; Cannabinoid Receptor Ag | 2016 |
Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats.
Topics: Animals; Benzoxazoles; Carbachol; Disease Models, Animal; Hypothalamic Area, Lateral; Male; Microinj | 2016 |
A study of cannabinoid-1 receptors during the early phase of excitotoxic damage to rat spinal locomotor networks in vitro.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease | 2016 |
Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Benzoxazines; Cannabinoid Recep | 2016 |
The Influence of the CB1 Receptor Ligands on the Schizophrenia-Like Effects in Mice Induced by MK-801.
Topics: Animals; Antipsychotic Agents; Cannabinoid Receptor Modulators; Disease Models, Animal; Dizocilpine | 2016 |
Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Aripiprazole; Ataxin-3; Brain; Disease | 2016 |
Role of orexin-2 and CB1 receptors within the periaqueductal gray matter in lateral hypothalamic-induced antinociception in rats.
Topics: Animals; Carbachol; Disease Models, Animal; Dose-Response Relationship, Drug; Hypothalamic Area, Lat | 2017 |
Activation of cannabinoid receptors elicits antidepressant-like effects in a mouse model of social isolation stress.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzoxazines; Cannabinoid Receptor Agonis | 2017 |
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.
Topics: Amidohydrolases; Analgesia; Animals; Benzamides; Carbamates; Carrageenan; Disease Models, Animal; In | 2008 |
Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Biogenic Amines; Brain Chemistry; Disease | 2009 |
Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1) agonist ACEA in the pentylenetetrazole-induced seizure in mice.
Topics: Analysis of Variance; Animals; Animals, Inbred Strains; Anticonvulsants; Arachidonic Acids; Arginine | 2009 |
Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Attention Deficit Disorder with Hypera | 2009 |
The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Brain; Cannabinoids; Cerebral Cortex; Disease Models, A | 2009 |
Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors.
Topics: Acetaminophen; Animals; Anti-Anxiety Agents; Anxiety; Arachidonic Acids; Behavior, Animal; Cannabino | 2009 |
Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Anxiety | 2009 |
Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.
Topics: Animals; Anticonvulsants; Benzoxazines; Brain; Calcium Channel Blockers; Cannabinoid Receptor Modula | 2009 |
A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy).
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Admini | 2010 |
Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids.
Topics: Action Potentials; Animals; Arachidonic Acids; Arthritis, Experimental; Dinoprostone; Disease Models | 2010 |
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.
Topics: Animals; Anxiety; Brain; Carbolines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2010 |
WAG/Rij rats show a reduced expression of CB₁ receptors in thalamic nuclei and respond to the CB₁ receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges.
Topics: Analysis of Variance; Animals; Benzoxazines; Disease Models, Animal; Electroencephalography; Epileps | 2010 |
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Modulators; Disease Models, Animal; Excitatory Amino | 2011 |
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
Topics: Analgesics; Animals; Bone Neoplasms; Camphanes; Cannabinoids; Cell Line, Tumor; Disease Models, Anim | 2010 |
Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Topics: Anesthesia; Animals; Arachidonic Acids; Camphanes; Cannabinoid Receptor Modulators; Central Nervous | 2010 |
Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cells, Cultured; Cholestasis; Disease M | 2010 |
Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats.
Topics: Administration, Oral; Animals; Brain; Conditioning, Classical; Disease Models, Animal; Dose-Response | 2010 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodop | 2010 |
Residual effects of focal brain ischaemia upon cannabinoid CB(1) receptor density and functionality in female rats.
Topics: Animals; Autoradiography; Brain; Brain Ischemia; Cyclohexanols; Disease Models, Animal; Estradiol; E | 2011 |
Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.
Topics: Action Potentials; Afferent Pathways; Age Factors; Animals; Arthralgia; Benzamides; Carbamates; Dicl | 2011 |
MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice.
Topics: Animals; Azetidines; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Dose-Response Rel | 2011 |
Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal.
Topics: Animals; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Modulators; Disease Models, Anima | 2011 |
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Topics: Animals; Antidepressive Agents; Arachidonic Acids; Benzamides; Cannabinoid Receptor Modulators; Carb | 2011 |
The cannabinoid receptor CB₁ inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response.
Topics: Animals; Arachidonic Acids; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corticosterone; Dise | 2011 |
A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Disease Models, Animal; Drug Synergism; E | 2011 |
Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
Topics: Analgesics; Analysis of Variance; Animals; Area Under Curve; Benzoxazines; Cannabinoid Receptor Agon | 2011 |
Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress.
Topics: Amygdala; Animals; Anxiety; Avoidance Learning; Benzoxazines; Cannabinoid Receptor Agonists; Cannabi | 2012 |
Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
Topics: Analysis of Variance; Animals; Animals, Newborn; Arachidonic Acids; Benzoxazines; Benzoxazoles; Biph | 2011 |
Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.
Topics: Absorptiometry, Photon; Animals; Disease Models, Animal; Dogs; Eating; Energy Metabolism; Female; Gl | 2012 |
Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease.
Topics: Action Potentials; Analysis of Variance; Animals; Benzoxazines; Brain; Disease Models, Animal; Drona | 2012 |
The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats.
Topics: Analysis of Variance; Anilides; Animals; Behavior, Addictive; Camphanes; Cinnamates; Cocaine-Related | 2012 |
Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Body Weight; Cannabinoid R | 2012 |
Contribution of hypothermia and CB1 receptor activation to protective effects of TAK-937, a cannabinoid receptor agonist, in rat transient MCAO model.
Topics: Amides; Animals; Benzofurans; Body Temperature; Disease Models, Animal; Hypothermia; Infarction, Mid | 2012 |
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Benzylamines; Chromones; Cisplatin; Cryopyrin-Associated Periodic Syndromes; Cyclams; Disea | 2012 |
Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Topics: Amides; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Cannabinoid Rece | 2013 |
Cannabinoid HU210 protects isolated rat stomach against impairment caused by serum of rats with experimental acute pancreatitis.
Topics: Acute Disease; Animals; Antiemetics; Cannabinoids; Cells, Cultured; Cytoprotection; Disease Models, | 2012 |
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
Topics: Animals; Anti-Anxiety Agents; Bromodeoxyuridine; Camphanes; Cannabidiol; Cannabinoid Receptor Antago | 2013 |
Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors.
Topics: Analysis of Variance; Animals; Anxiety; Brain; Disease Models, Animal; Dose-Response Relationship, D | 2013 |
Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Topics: Animals; Benzoxazines; Burns; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disea | 2004 |
The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice.
Topics: Analysis of Variance; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Recepto | 2004 |
Involvement of CB1-receptors and beta-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Consciousness; Disease Models, Animal; Drug In | 2005 |
The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis.
Topics: Acute Disease; Animals; Arachidonic Acids; Blood Pressure; Disease Models, Animal; Endocannabinoids; | 2005 |
Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain.
Topics: Acute Disease; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic A | 2006 |
Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.
Topics: Animals; Antidepressive Agents, Tricyclic; Cannabinoid Receptor Modulators; Cortisone; Depressive Di | 2006 |
Opposing modifications in intrinsic currents and synaptic inputs in post-traumatic mossy cells: evidence for single-cell homeostasis in a hyperexcitable network.
Topics: Animals; Animals, Newborn; Computer Simulation; Craniocerebral Trauma; Disease Models, Animal; Dose- | 2007 |
Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.
Topics: Animals; Arachidonic Acids; Bile Ducts; Blood Flow Velocity; Blood Pressure; Blotting, Western; Caps | 2006 |
Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy.
Topics: Action Potentials; Animals; Animals, Newborn; Benzoxazines; Cells, Cultured; Disease Models, Animal; | 2007 |
Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray.
Topics: Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Cannabinoids; Disease Models, Animal; Dose-Re | 2007 |
Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro.
Topics: Animals; Arachidonic Acids; Benzoxazines; Blood Pressure; Cannabinoids; Disease Models, Animal; Dose | 2007 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Anim | 2007 |
Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus.
Topics: Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Benzodiazepines; Benzoxazines; Calciu | 2007 |
Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship | 2007 |
Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Topics: Aging; Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Benzoxazin | 2007 |
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
Topics: Amidohydrolases; Animals; Blood Pressure; Cannabinoid Receptor Modulators; Carbon Tetrachloride; Dis | 2007 |
The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Topics: Analgesics; Analysis of Variance; Animals; Benzoxazines; Cannabinoids; Disease Models, Animal; Dose- | 2007 |
Actions of N-arachidonyl-glycine in a rat neuropathic pain model.
Topics: Analgesics; Animals; Arachidonic Acids; Area Under Curve; Camphanes; Disease Models, Animal; Dose-Re | 2008 |
The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonist | 2007 |
CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.
Topics: Amygdala; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Brain; | 2008 |
Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Cannabinoid Rece | 2007 |
Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: interaction between opioid and cannabinoid systems.
Topics: Animals; Anticonvulsants; Bile Ducts; Cannabinoid Receptor Modulators; Cholestasis; Disease Models, | 2008 |
Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Ant | 2007 |
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
Topics: Analgesics; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carrier Proteins; Disease M | 2007 |
Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia.
Topics: Acoustic Stimulation; Action Potentials; Animals; Biological Clocks; Brain; Cyclohexanols; Disease M | 2008 |
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Arachidonic Acids; Benzamides; Benzomorphans; Cannabin | 2008 |